Tauriga Sciences, INC.: directors' dealings · United States · SEC (Form 4)

About Tauriga Sciences, INC.

Tauriga Sciences, Inc. is a United States-based micro-cap life sciences company whose public reporting and legacy disclosures place it in the broad Health & Pharma / consumer wellness universe. For investors, it is best understood as a small, speculative commercial-development platform rather than a conventional large-scale pharmaceutical issuer. The company was founded in 2003 and has evolved over time from an earlier corporate structure into a business focused on proprietary products, brand development, and selective acquisition or licensing opportunities. Tauriga has described itself in SEC filings as operating in the life sciences technology and consumer-products space, with headquarters history that includes Danbury, Connecticut, Midtown Manhattan in New York City, and later Wappingers Falls, New York. It is a United States company, and for market-reference purposes it is discussed in the context of the U.S. listed-company universe tied to NYSE/NASDAQ-style public-market coverage, although the business has historically been associated with the OTC environment. The company’s main commercial theme has been product development, distribution, and licensing. Its best-known brand is Tauri-Gum™, a proprietary chewing-gum platform that has been marketed in CBD and CBG-infused versions, along with other functional formulations and limited-edition flavors. SEC materials also reference adjacent product concepts and a pharmaceutical-development initiative centered on a more advanced, potentially prescription-oriented version of Tauri-Gum. In practice, this means Tauriga has tried to combine consumer wellness branding with a longer-term optionality in pharma-style development. The company has also used subsidiaries and corporate reorganization to support those aims, while continuing to evaluate acquisition candidates and other revenue opportunities. From a competitive standpoint, Tauriga does not appear to compete head-to-head with large-cap pharmaceutical leaders. Instead, it operates in niche categories where differentiation, brand recognition, formulation IP, and channel access matter more than scale. That leaves the company exposed to meaningful execution risk, regulatory uncertainty, and financing dependence, but it also creates upside if a product line gains traction. Historically, its commercial emphasis has been on the New York metropolitan area and broader Northeast U.S. distribution, supported by e-commerce and selective retail pathways. Recent public disclosures suggest a continued focus on CBD/CBG consumer products, online commercialization, and pharmaceutical development initiatives, alongside the normal capital-markets constraints that affect micro-cap issuers. For French, Belgian, and Swiss investors, the key takeaway is that Tauriga Sciences is a high-risk, low-visibility U.S. listed health-and-wellness story with changing strategic priorities, limited scale, and a strong dependence on product execution and financing discipline. Any analysis should therefore emphasize corporate flexibility, dilution risk, and the uncertainty of future commercial adoption rather than assuming stable operating momentum.